Stockscreener 앱 받기
2.35
11.90%
0.25
시간 외 거래:
2.36
0.010
+0.43%
전일 마감가:
$2.10
열려 있는:
$2.05
하루 거래량:
2.19M
Relative Volume:
0.46
시가총액:
$189.46M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-117.50
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
+0.00%
1개월 성능:
-2.08%
6개월 성능:
+179.76%
1년 성능:
+99.15%
1일 변동 폭
$2.03
$2.40
1주일 범위
$2.03
$2.40
52주 변동 폭
$0.40
$3.095
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.35 | 341.87M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest
CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest
CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest
CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest
Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - GuruFocus
CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks
CytomX Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Posts Q2 2025 Financials, Announces Positive CX-2051 Results, and Extends Runway to Q2 2027. - AInvest
CytomX Therapeutics Files $250M Mixed Securities Shelf for Future Fundraising - AInvest
CytomX Reports Q2 Revenue Drop of 26%, Narrows Operating Losses Amid Pipeline Progress - AInvest
CytomX (CTMX) Q2 Revenue Drops 26% - The Motley Fool
CytomX (CTMX) Q2 Revenue Drops 26% - Nasdaq
CytomX Therapeutics reports Q2 EPS 0c, consensus (6c) - TipRanks
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - Yahoo Finance
CytomX Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
CytomX Therapeutics Inc Q2 2025 Earnings: EPS at $0.00 Beats Estimate, Revenue Surges to $18.7 Million - GuruFocus
CytomX Therapeutics files $250M mixed securities shelf - AInvest
CytomX Therapeutics Q2 Revenue Beats Estimates, Earnings Up 23.5M - AInvest
CytomX Therapeutics beats Q2 revenue estimates - MarketScreener
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update | CTMX Stock News - GuruFocus
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
CytomX Therapeutics to Report Second Quarter 2025 Financial Resu - GuruFocus
CytomX Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Oppenheimer Initiates Coverage on CytomX Therapeutics (NASDAQ:CTMX) - MarketBeat
What are the technical indicators suggesting about CytomX Therapeutics Inc.Explosive earning power - Jammu Links News
Is CytomX Therapeutics Inc. a good long term investmentGame-changing returns - Jammu Links News
How volatile is CytomX Therapeutics Inc. stock compared to the marketGame-changing capital returns - Jammu Links News
CytomX Therapeutics (NASDAQ:CTMX) shareholders have earned a 79% return over the last year - Yahoo Finance
Why is CytomX Therapeutics Inc. stock attracting strong analyst attentionCapitalize on market trends with confidence - Jammu Links News
What institutional investors are buying CytomX Therapeutics Inc. stockCapitalize on fast-moving trading opportunities - Jammu Links News
What is the risk reward ratio of investing in CytomX Therapeutics Inc. stockCapitalize on market trends before they peak - Jammu Links News
Does CytomX Therapeutics Inc. stock perform well during market downturnsFree Capital Growth Strategies - Jammu Links News
What are analysts’ price targets for CytomX Therapeutics Inc. in the next 12 monthsInvest smarter with data-backed trading alerts - Jammu Links News
What are the latest earnings results for CytomX Therapeutics Inc.Overwhelming financial success - Jammu Links News
What is CytomX Therapeutics Inc. company’s growth strategyRapid capital growth - Jammu Links News
What makes CytomX Therapeutics Inc. stock price move sharplyFree Trading Psychology Coaching - Jammu Links News
How strong is CytomX Therapeutics Inc. company’s balance sheetMaximize returns with effective portfolio management - Jammu Links News
CytomX Therapeutics Inc.’s Price Action Aligns with Quant SignalsSwing Trading Entry Signals Suggest Opportunity Zone - metal.it
Should I hold or sell CytomX Therapeutics Inc. stock in 2025Swing Trade Review With Proven Results - jammulinksnews.com
CytomX Therapeutics' CX-2051 Shows Promising Results in Colorectal Cancer Treatment: Oppenheimer Analyst Initiates Coverage with Outperform Rating - AInvest
Lexeo Therapeutics Analyst Begins Coverage on Bullish Note; Top 3 Initiations for Thursday - AInvest
This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 | CTMX Stock News - GuruFocus
CytomX Therapeutics: Oppenheimer initiates coverage with Outperform rating, PT $7. - AInvest
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 - The Manila Times
CytomX Therapeutics Sets Q2 Earnings Date: Biotech Leader to Update on Masked Biologics Progress - Stock Titan
Oppenheimer initiates CytomX Therapeutics stock with Outperform rating By Investing.com - Investing.com Nigeria
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):